Identifying biomarkers that predict blood clots in ovarian cancer patients
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10931748
This study is looking at how ovarian cancer and chemotherapy might increase the risk of blood clots, and it aims to find specific markers in patients' tumors and blood that can help identify who is more likely to have this risk, so doctors can provide safer and more personalized treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10931748 on ClinicalTrials.gov |
What this research studies
This research investigates the risk of venous thromboembolism (VTE) in ovarian cancer patients, particularly those undergoing chemotherapy. By analyzing tumor specimens and blood samples from a cohort of patients, the study aims to identify novel biomarkers that indicate a higher risk of developing blood clots. The researchers will focus on cancer cell products, specifically looking at the role of mitochondria and podoplanin in increasing VTE risk. This approach seeks to improve patient safety by allowing for targeted anticoagulation therapy rather than a blanket approach for all patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer patients who are receiving or have received neoadjuvant chemotherapy.
Not a fit: Patients with ovarian cancer who are not undergoing chemotherapy or those with other underlying conditions that preclude participation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans that reduce the risk of blood clots in ovarian cancer patients undergoing chemotherapy.
How similar studies have performed: Previous research has shown success in identifying risk factors for VTE in cancer patients, but this study's focus on tumor-specific biomarkers is a novel approach.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AFSHAR-KHARGHAN, VAHID — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: AFSHAR-KHARGHAN, VAHID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.